Molecule intelOpportunity: Moderate0

Hydroxyprogesterone

4 brands · 3 companies · product forms

2 DRAP alerts

Opportunity snapshot

Launch attractiveness
36
Market saturation
8
Price room
0
Regulatory risk
70
4
brands
3
companies
Rs 254.84
median price
2
price points
1.23x
price spread
65
confidence %

Who competes here

Top companies by brand count — concentrated market · leader share 50%

Price room

Across observed sources and strengths
CheapestRs 228.26
MedianRs 254.84
Most expensiveRs 281.43
Spread1.23×
Sources: DRAP-official, Servaid

Only 2 trusted price points; variation not scored (low data).

Brands & products on the market

Sample of 4 live products for Hydroxyprogesterone — each links to its own medicine page.

Regulatory alerts

Recall exposurelatest 2025-07-09
Suspension of marketing authorisations of 17-Hydroxyprogesterone caproate (17- OHPC) due t
Recall Alert: RECALL OF PRODUCTS CONTAINING HYDROXYPROGESTERONE CAPROATE

Why this score

Launch attractiveness

40% supply-gap(45) + 25% price-variation(0) + 20% low-competition(92) + 15% supply-disruption(40), damped by confidence(65). Higher = more attractive, less crowded opportunity.

Market saturation

3 canonical companies and 4 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

Only 2 trusted price points; variation not scored (low data).

Regulatory risk

2 DRAP alert(s), latest 2025-07-09 incl. recall/safety.

Confidence

Reduced by: sparse price data, no ATC code.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.